AB250
Aligning Medicaid prices with Medicare
Date of Vote: April 25, 2023
Chamber of Origin: SenateAB250 from Nevada's 2023 legislative session aims to align the state's prescription drug prices with those negotiated by Medicare under the federal Inflation Reduction Act. Set to take effect in 2026, the bill ensures that Nevada residents, particularly seniors, benefit from reduced drug costs achieved through federal negotiations. Passed along party lines, AB250 reflects a significant effort to make healthcare more affordable in the state by leveraging federal policy to control prescription drug prices
Turning Point Action’s Position
Voted YEA
130% REPUBLICANS0% DEMOCRATS0% INDEPENDENTS
VOTED NAY
7100% REPUBLICANS0% DEMOCRATS0% INDEPENDENTS
Search by Party
Voted yea
Dallas HarrisState SenateNevada
Session Score:11.54
Dina NealState SenateNevada
Session Score:15.38
Edgar FloresState SenateNevada
Session Score:11.54
Fabian DoñateState SenateNevada
Session Score:15.38
James OhrenschallState SenateNevada
Session Score:15.38
Julie PazinaState SenateNevada
Session Score:15.38
Voted nay
Carrie A. BuckState SenateNevada
Session Score:80.77
Heidi Seevers GansertState SenateNevada
Session Score:69.23
Ira HansenState SenateNevada
Session Score:96.15
Jeff StoneState SenateNevada
Session Score:96.15
Lisa KrasnerState SenateNevada
Session Score:88.46
Pete GoicoecheaState SenateNevada
Session Score:92.31
Not voting
No legislators have been found in this category
Present
No legislators have been found in this category
Abstaining
No legislators have been found in this category
DONATE
Our mission is unachievable without your help. We accept a wide range of donation options to ensure the preservation of this great country!
Donate NowDonate Now